Stroke Trials Registry

Piracetam
Nootropil®

Action
Mechanism of action unknown; increases cerebral blood flow; inhibits platelet aggregation.

Status
Phase III trial (PASS) reported 1997. Piracetam did not influence outcome when given within 12 hours of acute stroke. PASS II trial ongoing as of 2/01. Small trial suggests benefit of piracetam for aphasia after stroke.

Trial(s)
= Ongoing
= Completed

Effect of piracetam on recovery and rehabilitation after stroke

PASS II Piracetam Acute Stroke Study II

PASS Piracetam in Acute Stroke Study

Web Links and Publications

UCB Web Site.

Pharmacological treatment for aphasia following stroke (Cochrane Review).
Cochrane Database Syst Rev. 2001;4:CD000424.

Major Ongoing Stroke Trials.

Major Ongoing Stroke Trials.
Stroke 2000 Oct;31(10):2536-42

Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients.
Stroke 2000 Sep;31(9):2112-6.

Piracetam for acute ischaemic stroke.
Cochrane Database Syst Rev. 2000;(2):CD000419.

Economic evaluation of Nootropil in the treatment of acute stroke in France.
Pharmacol Res 1997 Nov;36(5):373-80

Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
Stroke 1997 Dec;28(12):2347-2352

Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study.
Clin Neuropharmacol 1994 Aug;17(4):320-31

UID: 34